Volume 65, Issue 1 pp. 81-87

Rheumatoid Arthritis

Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis

Dezsö Körmendy,

Dezsö Körmendy

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany

Mr. Dezsö Körmendy and Dr. Holger Hoff contributed equally to this work.

Search for more papers by this author

Holger Hoff,

Holger Hoff

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany

Mr. Dezsö Körmendy and Dr. Holger Hoff contributed equally to this work.

Search for more papers by this author

Paula Hoff,

Paula Hoff

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany

Search for more papers by this author

Barbara M. Bröker,

Barbara M. Bröker

Universität Greifswald, Greifswald, Germany

Dr. Bröker has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than $10,000) and receives licensing fees from Becton Dickinson for the use of BNI3 monoclonal antibodies.

Search for more papers by this author

Gerd-Rüdiger Burmester,

Gerd-Rüdiger Burmester

Charité Universitätsmedizin Berlin, Berlin, Germany

Dr. Burmester has received consulting fees and speaking fees from Bristol-Myers Squibb (less than $10,000).

Search for more papers by this author

Monika C. Brunner-Weinzierl,

Corresponding Author

Monika C. Brunner-Weinzierl

[email protected]

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany, and Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany

Department of Pediatrics, Otto-von-Guericke Universität Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanySearch for more papers by this author

Dezsö Körmendy,

Dezsö Körmendy

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany

Mr. Dezsö Körmendy and Dr. Holger Hoff contributed equally to this work.

Search for more papers by this author

Holger Hoff,

Holger Hoff

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany

Mr. Dezsö Körmendy and Dr. Holger Hoff contributed equally to this work.

Search for more papers by this author

Paula Hoff,

Paula Hoff

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany

Search for more papers by this author

Barbara M. Bröker,

Barbara M. Bröker

Universität Greifswald, Greifswald, Germany

Dr. Bröker has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than $10,000) and receives licensing fees from Becton Dickinson for the use of BNI3 monoclonal antibodies.

Search for more papers by this author

Gerd-Rüdiger Burmester,

Gerd-Rüdiger Burmester

Charité Universitätsmedizin Berlin, Berlin, Germany

Dr. Burmester has received consulting fees and speaking fees from Bristol-Myers Squibb (less than $10,000).

Search for more papers by this author

Monika C. Brunner-Weinzierl,

Corresponding Author

Monika C. Brunner-Weinzierl

[email protected]

Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany, and Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany

Department of Pediatrics, Otto-von-Guericke Universität Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanySearch for more papers by this author

First published: 08 October 2012

https://doi.org/10.1002/art.37714

Citations: 29

Share a link

Email
Wechat
Bluesky

Abstract

Objective

The importance of the costimulatory molecules CD28 and CTLA-4 in the pathologic mechanism of rheumatoid arthritis (RA) has been demonstrated by genetic associations and the successful clinical application of CTLA-4Ig for the treatment of RA. This study was undertaken to investigate the role of the CTLA-4/CD28 axis in the local application of CTLA-4Ig in the synovial fluid (SF) of RA patients.

Methods

Quantitative polymerase chain reaction was used to analyze the expression of proinflammatory and antiinflammatory cytokines in ex vivo fluorescence-activated cell sorted CTLA-4+ and CTLA-4− T helper cells from the peripheral blood and SF of RA patients. T helper cells were also analyzed for cytokine expression in vitro after the blockade of CTLA-4 by anti–CTLA-4 Fab fragments or of B7 (CD80/CD86) molecules by CTLA-4Ig.

Results

CTLA-4+ T helper cells were unambiguously present in the SF of all RA patients examined, and they expressed increased amounts of interferon-γ (IFNγ), interleukin-17 (IL-17), and IL-10 as compared to CTLA-4− T helper cells. The selective blockade of CTLA-4 in T helper cells from the SF in vitro led to increased levels of IFNγ, IL-2, and IL-17. The concomitant blockade of CD28 and CTLA-4 in T helper cells from RA SF by CTLA-4Ig in vitro resulted in reduced levels of the proinflammatory cytokines IFNγ and IL-2 and increased levels of the antiinflammatory cytokines IL-10 and transforming growth factor β.

Conclusion

Our ex vivo and in vitro results demonstrate that the CTLA-4/CD28 axis constitutes a drug target for not only the systemic, but potentially also the local, application of the costimulation blocking agent CTLA-4Ig for the treatment of RA.

REFERENCES

1 Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005; 64: 1427–30.
10.1136/ard.2004.029199
CAS PubMed Web of Science® Google Scholar
2 Pedersen JK, Svendsen AJ, Horslev-Petersen K. Prevalence of rheumatoid arthritis in the southern part of Denmark. Open Rheumatol J 2011; 5: 91–7.
10.2174/1874312901105010091
PubMed Google Scholar
3 Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41: 793–800.
10.1093/rheumatology/41.7.793
CAS PubMed Web of Science® Google Scholar
4 McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205–19.
10.1056/NEJMra1004965
CAS PubMed Web of Science® Google Scholar
5 Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336–47.
10.1038/nri1349
CAS PubMed Web of Science® Google Scholar
6 Brunner-Weinzierl MC, Hoff H, Burmester GR. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases. Arthritis Res Ther 2004; 6: 45–54.
10.1186/ar1158
CAS PubMed Web of Science® Google Scholar
7 Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 2008; 8: 153–60.
10.1038/nri2253
CAS PubMed Web of Science® Google Scholar
8 Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813–20.
10.4049/jimmunol.162.10.5813
CAS PubMed Web of Science® Google Scholar
9 Hoff H, Kolar P, Ambach A, Radbruch A, Brunner-Weinzierl MC. CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch. Mol Immunol 2010; 47: 1875–81.
10.1016/j.molimm.2010.03.017
CAS PubMed Web of Science® Google Scholar
10 Maszyna F, Hoff H, Kunkel D, Radbruch A, Brunner-Weinzierl MC. Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J Immunol 2003; 171: 3459–66.
10.4049/jimmunol.171.7.3459
CAS PubMed Web of Science® Google Scholar
11 Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600–3.
10.1126/science.1202947
CAS PubMed Web of Science® Google Scholar
12 Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11: 852–63.
10.1038/nri3108
CAS PubMed Web of Science® Google Scholar
13 Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester GR, et al. Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28^null T cells. J Immunol 2009; 182: 5342–51.
10.4049/jimmunol.0801624
CAS PubMed Web of Science® Google Scholar
14 Kim YO, Kim HJ, Kim SK, Chung JH, Hong SJ. Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis. Clin Chem Lab Med 2010; 48: 345–53.
10.1515/CCLM.2010.074
CAS PubMed Web of Science® Google Scholar
15 Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41: 1313–8.
10.1038/ng.479
CAS PubMed Web of Science® Google Scholar
16 Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506–11.
10.1038/nature01621
CAS PubMed Web of Science® Google Scholar
17 Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907–15.
10.1056/NEJMoa035075
CAS PubMed Web of Science® Google Scholar
18 Castan J, Tenner-Racz K, Racz P, Fleischer B, Broker BM. Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues. Immunology 1997; 90: 265–71.
10.1046/j.1365-2567.1997.00162.x
CAS PubMed Web of Science® Google Scholar
19 Kolar P, Knieke K, Hegel JK, Quandt D, Burmester GR, Hoff H, et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum 2009; 60: 123–32.
10.1002/art.24181
CAS PubMed Web of Science® Google Scholar
20 Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, et al. Pathogen-induced human T_H17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012; 484: 514–8.
10.1038/nature10957
CAS PubMed Web of Science® Google Scholar
21 Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional T_H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843–50.
10.1038/nm1592
CAS PubMed Web of Science® Google Scholar
22 Rudolph M, Hebel K, Miyamura Y, Maverakis E, Brunner-Weinzierl MC. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4⁺ T cells in vivo. J Immunol 2011; 186: 5580–9.
10.4049/jimmunol.1003381
CAS PubMed Web of Science® Google Scholar
23 Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71–109.
10.1146/annurev-immunol-031210-101312
CAS PubMed Web of Science® Google Scholar
24 Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006; 33: 2162–6.
CAS PubMed Web of Science® Google Scholar
25 Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005; 5: 1245–54.
10.1517/14712598.5.9.1245
CAS PubMed Web of Science® Google Scholar
26 Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68: 1220–7.
10.1136/ard.2008.091876
CAS PubMed Web of Science® Google Scholar
27 Hollander JL, Brown EM Jr, Jessar RA, Brown CY. Hydrocortisone and cortisone injected into arthritic joints: comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc 1951; 147: 1629–35.
10.1001/jama.1951.03670340019005
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume65, Issue1

January 2013

Pages 81-87

Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis

Abstract

Objective

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis

Abstract

Objective

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Related

Information